Skip to main content

Table 5 Summary of hemostasis, admission and re-presentation rates comparing treatment (Floseal® (Baxter, USA)) to control (traditional packing methods)

From: Management of Persistent Epistaxis Using Floseal Hemostatic Matrix vs. traditional nasal packing: a prospective randomized control trial

  Treatment (Floseal) (N = 13) Control
(N = 13)
p-valuea
Hemostasis Post-Treatment 10 (76.9%) 11 (84.6%) 1.0000
Hemostasis at 48-h 10 (76.9%) 9 (69.2%) 1.0000
Admission Required 2 (15.4%) 6 (46.1%) 0.2016
30 Day ED Re-Presentation 2 (15.4%) 6 (46.1%) 0.2016
Adverse Events 0 (0.0%) 0 (0.0%) 1.0000
  1. a α = 0.05, significant results in bold using Fisher’s exact test